Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors
Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors, Published online: 03 January 2018; doi:10.1038/nrclinonc.2017.210Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Haematological cancer: Brentuximab effective in untreated Hodgkin lymphoma
Haematological cancer: Brentuximab effective in untreated Hodgkin lymphoma, Published online: 28 December 2017; doi:10.1038/nrclinonc.2017.209Haematological cancer: Brentuximab effective in untreated Hodgkin lymphoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 28, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Perioperative events influence cancer recurrence risk after surgery
Perioperative events influence cancer recurrence risk after surgery, Published online: 28 December 2017; doi:10.1038/nrclinonc.2017.194Despite the achievement of locoregional control, a third of patients undergoing surgery for cancer will have disease recurrence. In this Review, the authors describe the potential to optimize the outcomes of patients with cancer by minimizing inflammation and activation of the sympathetic nervous system in the perioperative period, which is often achievable with simple and cost-effective changes in patient-management strategies. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 28, 2017 Category: Cancer & Oncology Authors: Jonathan G. Hiller Nicholas J. Perry George Poulogiannis Bernhard Riedel Erica K. Sloan Source Type: research
Palliative care: Anamorelin provides benefit to patients with cachexia
Palliative care: Anamorelin provides benefit to patients with cachexia, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.204Palliative care: Anamorelin provides benefit to patients with cachexia (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Bladder cancer: Multi-omic profiling refines the molecular view
Bladder cancer: Multi-omic profiling refines the molecular view, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.195Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease for which treatment has, historically, lagged behind that of other solid tumour types. A more detailed understanding of the biology of individual tumours, and the identification of molecular features providing prognostic and predictive information is key to the application of personalized care for patients with MIBC. The publication of a study of 412 samples now provides such data. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Carolyn D. Hurst Margaret A. Knowles Source Type: research
Prostate cancer: Genomic information improves risk prediction
Prostate cancer: Genomic information improves risk prediction, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.205Prostate cancer: Genomic information improves risk prediction (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Immunotherapy: dMMR presents opportunities to enhance immunotherapy
Immunotherapy: dMMR presents opportunities to enhance immunotherapy, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.203Immunotherapy: dMMR presents opportunities to enhance immunotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research
The evidence framework for precision cancer medicine
The evidence framework for precision cancer medicine, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.186Precision cancer medicine has the potential to dramatically improve the outcomes of patients with cancer; however, despite the precise nature of the therapies involved, generating reliable evidence of efficacy is often challenging. In this Perspective, the authors describe the challenges and potential solutions that might address the need for evidence in precision cancer medicine. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Jeffrey A. Moscow Tito Fojo Richard L. Schilsky Source Type: research
Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm
Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.176In 2017, three groundbreaking immunotherapies for relapsed and/or refractory B-cell acute lymphoblastic leukaemia (ALL) were approved based on impressive outcomes observed in clinical trials. Additional breakthroughs included seminal research into ALL genomics and the importance of adherence to chemotherapy, which will have direct implications for clinical care. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: David T. Teachey Stephen P. Hunger Source Type: research
Lung cancer: OSNA enables more accurate detection of micrometastases
Lung cancer: OSNA enables more accurate detection of micrometastases, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.206Lung cancer: OSNA enables more accurate detection of micrometastases (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Colorectal cancer: Defining location effect in nonmetastatic disease
Colorectal cancer: Defining location effect in nonmetastatic disease, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.202Colorectal cancer: Defining location effect in nonmetastatic disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Immunotherapy: No effect of CAR-T-cell infusion on infection risk
Immunotherapy: No effect of CAR-T-cell infusion on infection risk, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.200Immunotherapy: No effect of CAR-T-cell infusion on infection risk (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Lung cancer: First-in-man phase I trial with lorlatinib
Lung cancer: First-in-man phase I trial with lorlatinib, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.201Lung cancer: First-in-man phase I trial with lorlatinib (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
CAR T cells — what have we learnt?
CAR T cells — what have we learnt?, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.196CAR T cells — what have we learnt? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Source Type: research
Pancreatic cancer: Mass spectrometry indicates malignant potential
Pancreatic cancer: Mass spectrometry indicates malignant potential, Published online: 12 December 2017; doi:10.1038/nrclinonc.2017.199Pancreatic cancer: Mass spectrometry indicates malignant potential (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 12, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
